Vitiligo research moves past cosmetic, targets immune system

New editorial in The Lancet highlights how vitiligo, long dismissed as a cosmetic issue, is now understood as an immune-mediated condition. This deeper understanding of its pathophysiology — the immune-driven loss of melanocytes — is enabling targeted new therapies. It reframes the condition from a skin-deep flaw to a systemic immune response.